Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302


Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal Study.

Speake C, Bahnson HT, Wesley JD, Perdue N, Friedrich D, Pham MN, Lanxon-Cookson E, Kwok WW, Sehested Hansen B, von Herrath M, Greenbaum CJ.

Front Immunol. 2019 Sep 13;10:2023. doi: 10.3389/fimmu.2019.02023. eCollection 2019.


CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor.

Pagni PP, Wolf A, Lo Conte M, Yeh R, Fu G, Liu F, von Herrath M, Coppieters K.

Diabetologia. 2019 Sep;62(9):1727-1729. doi: 10.1007/s00125-019-4893-2. Epub 2019 May 17. No abstract available.


Regulatory Immune Mechanisms beyond Regulatory T Cells.

Christoffersson G, von Herrath M.

Trends Immunol. 2019 Jun;40(6):482-491. doi: 10.1016/ Epub 2019 May 14. Review.


Case Reports of Pre-clinical Replication Studies in Metabolism and Diabetes.

von Herrath M, Pagni PP, Grove K, Christoffersson G, Tang-Christensen M, Karlsen AE, Petersen JS.

Cell Metab. 2019 Apr 2;29(4):795-802. doi: 10.1016/j.cmet.2019.02.004. Epub 2019 Mar 14. Review.


The Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes.

Coppieters K, von Herrath M.

Front Med (Lausanne). 2018 Oct 9;5:283. doi: 10.3389/fmed.2018.00283. eCollection 2018. Review.


Loss of IDO1 Expression From Human Pancreatic β-Cells Precedes Their Destruction During the Development of Type 1 Diabetes.

Anquetil F, Mondanelli G, Gonzalez N, Rodriguez Calvo T, Zapardiel Gonzalo J, Krogvold L, Dahl-Jørgensen K, Van den Eynde B, Orabona C, Grohmann U, von Herrath MG.

Diabetes. 2018 Sep;67(9):1858-1866. doi: 10.2337/db17-1281. Epub 2018 Jun 26.


Distinct Housing Conditions Reveal a Major Impact of Adaptive Immunity on the Course of Obesity-Induced Type 2 Diabetes.

Sbierski-Kind J, Kath J, Brachs S, Streitz M, von Herrath MG, Kühl AA, Schmidt-Bleek K, Mai K, Spranger J, Volk HD.

Front Immunol. 2018 May 28;9:1069. doi: 10.3389/fimmu.2018.01069. eCollection 2018.


Oral insulin does not alter gut microbiota composition of NOD mice.

Kihl P, Krych L, Buschard K, Wesley JD, Kot W, Hansen AK, Nielsen DS, von Herrath MG.

Diabetes Metab Res Rev. 2018 Sep;34(6):e3010. doi: 10.1002/dmrr.3010. Epub 2018 May 1.


Suppression of diabetes by accumulation of non-islet-specific CD8+ effector T cells in pancreatic islets.

Christoffersson G, Chodaczek G, Ratliff SS, Coppieters K, von Herrath MG.

Sci Immunol. 2018 Mar 23;3(21). pii: eaam6533. doi: 10.1126/sciimmunol.aam6533.


Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications.

Sidney J, Vela JL, Friedrich D, Kolla R, von Herrath M, Wesley JD, Sette A.

BMC Immunol. 2018 Mar 21;19(1):12. doi: 10.1186/s12865-018-0250-3.


OAS1 is not associated with MHC class I hyperexpression in the islets of donors with T1D regardless of disease duration.

Sabouri S, Mikulski Z, von Herrath MG.

Clin Immunol. 2018 Jun;191:34-36. doi: 10.1016/j.clim.2018.03.006. Epub 2018 Mar 15. No abstract available.


α Cell Function and Gene Expression Are Compromised in Type 1 Diabetes.

Brissova M, Haliyur R, Saunders D, Shrestha S, Dai C, Blodgett DM, Bottino R, Campbell-Thompson M, Aramandla R, Poffenberger G, Lindner J, Pan FC, von Herrath MG, Greiner DL, Shultz LD, Sanyoura M, Philipson LH, Atkinson M, Harlan DM, Levy SE, Prasad N, Stein R, Powers AC.

Cell Rep. 2018 Mar 6;22(10):2667-2676. doi: 10.1016/j.celrep.2018.02.032.


The shifting paradigm of a "cure" for type 1 diabetes: is technology replacing immune-based therapies?

Pettus J, Von Herrath M.

Acta Diabetol. 2018 Feb;55(2):117-120. doi: 10.1007/s00592-017-1069-8. Epub 2017 Nov 29.


Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy.

Coppieters K, von Herrath M.

Cell Metab. 2017 Oct 3;26(4):595-597. doi: 10.1016/j.cmet.2017.09.016.


Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.

Rydén AK, Perdue NR, Pagni PP, Gibson CB, Ratliff SS, Kirk RK, Friesen TJ, Haase C, Coppieters K, von Herrath MG, Boursalian TE.

J Autoimmun. 2017 Nov;84:65-74. doi: 10.1016/j.jaut.2017.07.006. Epub 2017 Jul 12.


β-Cell mass versus function in type 1 diabetes mellitus: truth or dare?

Rodriguez-Calvo T, Atkinson M, von Herrath M.

Nat Rev Endocrinol. 2017 Sep;13(9):1. doi: 10.1038/nrendo.2017.83. Epub 2017 Jul 7. No abstract available.


Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice.

Grönholm J, Pagni PP, Pham MN, Gibson CB, Macomber PF, Vela JL, von Herrath M, Lenardo MJ.

Diabetologia. 2017 Aug;60(8):1475-1482. doi: 10.1007/s00125-017-4276-5. Epub 2017 Apr 28.


Alpha cells, the main source of IL-1β in human pancreas.

Anquetil F, Sabouri S, Thivolet C, Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N, Schneider D, Castillo E, Lajevardi Y, von Herrath MG.

J Autoimmun. 2017 Jul;81:68-73. doi: 10.1016/j.jaut.2017.03.006. Epub 2017 Mar 18.


Increase in Pancreatic Proinsulin and Preservation of β-Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset.

Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N, Castillo E, Lajevardi Y, Krogvold L, Dahl-Jørgensen K, von Herrath MG.

Diabetes. 2017 May;66(5):1334-1345. doi: 10.2337/db16-1343. Epub 2017 Jan 30.


Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.

Kirk RK, Pyke C, von Herrath MG, Hasselby JP, Pedersen L, Mortensen PG, Knudsen LB, Coppieters K.

Diabetes Obes Metab. 2017 May;19(5):705-712. doi: 10.1111/dom.12879. Epub 2017 Mar 10.


Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes: is change necessary?

Campbell-Thompson ML, Atkinson MA, Butler AE, Giepmans BN, von Herrath MG, Hyöty H, Kay TW, Morgan NG, Powers AC, Pugliese A, Richardson SJ, In't Veld PA.

Diabetologia. 2017 Apr;60(4):753-755. doi: 10.1007/s00125-016-4195-x. Epub 2017 Jan 9. No abstract available.


Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?

Kolb H, von Herrath M.

Cell Metab. 2017 Feb 7;25(2):233-241. doi: 10.1016/j.cmet.2016.10.009. Epub 2016 Nov 10. Review.


CD40L expression by CD4+ but not CD8+ T cells regulates antiviral immune responses in acute LCMV infection in mice.

Durlanik S, Loyal L, Stark R, Sercan Alp Ö, Hartung A, Radbruch A, von Herrath M, Matzmohr N, Frentsch M, Thiel A.

Eur J Immunol. 2016 Nov;46(11):2566-2573. doi: 10.1002/eji.201646420. Epub 2016 Sep 20.


A Deeper Look into Type 1 Diabetes - Imaging Immune Responses during Onset of Disease.

Christoffersson G, von Herrath MG.

Front Immunol. 2016 Aug 15;7:313. doi: 10.3389/fimmu.2016.00313. eCollection 2016. Review.


Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes.

Richardson SJ, Rodriguez-Calvo T, Gerling IC, Mathews CE, Kaddis JS, Russell MA, Zeissler M, Leete P, Krogvold L, Dahl-Jørgensen K, von Herrath M, Pugliese A, Atkinson MA, Morgan NG.

Diabetologia. 2016 Nov;59(11):2448-2458. doi: 10.1007/s00125-016-4067-4. Epub 2016 Aug 9.


The viral paradigm in type 1 diabetes: Who are the main suspects?

Rodriguez-Calvo T, Sabouri S, Anquetil F, von Herrath MG.

Autoimmun Rev. 2016 Oct;15(10):964-9. doi: 10.1016/j.autrev.2016.07.019. Epub 2016 Aug 1. Review.


Recent advances in understanding Type 1 Diabetes.

Christoffersson G, Rodriguez-Calvo T, von Herrath M.

F1000Res. 2016 Jan 27;5. pii: F1000 Faculty Rev-110. doi: 10.12688/f1000research.7356.1. eCollection 2016. Review.


Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse.

Pham MN, Gibson C, Rydén AK, Perdue N, Boursalian TE, Pagni PP, Coppieters K, Skonberg C, Porsgaard T, von Herrath M, Vela JL.

Clin Immunol. 2016 Mar;164:28-33. doi: 10.1016/j.clim.2016.01.013. Epub 2016 Jan 25.


Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.

Pham MN, von Herrath MG, Vela JL.

Front Immunol. 2016 Jan 11;6:651. doi: 10.3389/fimmu.2015.00651. eCollection 2015. Review.


A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.

Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT.

Diabetes. 2016 May;65(5):1310-6. doi: 10.2337/db15-0492. Epub 2015 Dec 30.


Erratum. Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the Pathogenesis of Type 1 Diabetes. Diabetes 2014;63:3880-3890.

Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, von Herrath MG.

Diabetes. 2016 Jan;65(1):303. doi: 10.2337/db16-er01. No abstract available.


New horizons in biomarker research.

Von Herrath M, Jarjour WN.

Clin Immunol. 2015 Nov;161(1):1. doi: 10.1016/j.clim.2015.09.005. Epub 2015 Sep 15. No abstract available.


Pancreatic Tissue Transplanted in TheraCyte Encapsulation Devices Is Protected and Prevents Hyperglycemia in a Mouse Model of Immune-Mediated Diabetes.

Boettler T, Schneider D, Cheng Y, Kadoya K, Brandon EP, Martinson L, von Herrath M.

Cell Transplant. 2016;25(3):609-14. doi: 10.3727/096368915X688939. Epub 2015 Aug 21.


Heterogeneity and Lobularity of Pancreatic Pathology in Type 1 Diabetes during the Prediabetic Phase.

Rodriguez-Calvo T, Suwandi JS, Amirian N, Zapardiel-Gonzalo J, Anquetil F, Sabouri S, von Herrath MG.

J Histochem Cytochem. 2015 Aug;63(8):626-36. doi: 10.1369/0022155415576543.


Immunotherapies and immune biomarkers in Type 1 diabetes: A partnership for success.

Rekers NV, von Herrath MG, Wesley JD.

Clin Immunol. 2015 Nov;161(1):37-43. doi: 10.1016/j.clim.2015.05.021. Epub 2015 Jun 27. Review.


CD4 T cell differentiation in type 1 diabetes.

Walker LS, von Herrath M.

Clin Exp Immunol. 2016 Jan;183(1):16-29. doi: 10.1111/cei.12672. Epub 2015 Jul 28. Review.


Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.

Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M.

Diabetes Care. 2015 Jun;38(6):979-88. doi: 10.2337/dc15-0144. No abstract available.


Factors impeding the discovery of an intervention-based treatment for type 1 diabetes.

von Herrath MG, Korsgren O, Atkinson MA.

Clin Exp Immunol. 2016 Jan;183(1):1-7. doi: 10.1111/cei.12656. Epub 2015 Jul 24. Review.


Enterovirus infection and type 1 diabetes: closing in on a link?

Rodriguez-Calvo T, von Herrath MG.

Diabetes. 2015 May;64(5):1503-5. doi: 10.2337/db14-1931. No abstract available.


The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice.

Sarikonda G, Sachithanantham S, Miller JF, Pagni PP, Coppieters KT, von Herrath M.

J Autoimmun. 2015 May;59:61-6. doi: 10.1016/j.jaut.2015.02.003. Epub 2015 Mar 13.


Enteroviruses, hygiene and type 1 diabetes: toward a preventive vaccine.

Drescher KM, von Herrath M, Tracy S.

Rev Med Virol. 2015 Jan;25(1):19-32. doi: 10.1002/rmv.1815. Epub 2014 Nov 27. Review.


BDC12-4.1 T-cell receptor transgenic insulin-specific CD4 T cells are resistant to in vitro differentiation into functional Foxp3+ T regulatory cells.

Sarikonda G, Fousteri G, Sachithanantham S, Miller JF, Dave A, Juntti T, Coppieters KT, von Herrath M.

PLoS One. 2014 Nov 13;9(11):e112242. doi: 10.1371/journal.pone.0112242. eCollection 2014.


The type 1 diabetes signature: hardwired to trigger inflammation?

Coppieters KT, von Herrath MG.

Diabetes. 2014 Nov;63(11):3581-3. doi: 10.2337/db14-0824. No abstract available.


Inflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes.

Yip L, Fuhlbrigge R, Taylor C, Creusot RJ, Nishikawa-Matsumura T, Whiting CC, Schartner JM, Akter R, von Herrath M, Fathman CG.

Diabetes. 2015 Feb;64(2):604-17. doi: 10.2337/db14-0803. Epub 2014 Sep 3.


Higher proinflammatory cytokine production and spontaneous activation in some type 1 and type 2 diabetic subjects.

Sarikonda G, Sachithanantham S, Pettus J, Rodriguez-Calvo T, Phatak S, Edelman S, von Herrath M.

Clin Immunol. 2014 Nov;155(1):27-9. doi: 10.1016/j.clim.2014.08.007. Epub 2014 Aug 27. No abstract available.


Potential viral pathogenic mechanism in human type 1 diabetes.

Schneider DA, von Herrath MG.

Diabetologia. 2014 Oct;57(10):2009-18. doi: 10.1007/s00125-014-3340-7. Epub 2014 Jul 30. Review.


CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients.

Fløyel T, Brorsson C, Nielsen LB, Miani M, Bang-Berthelsen CH, Friedrichsen M, Overgaard AJ, Berchtold LA, Wiberg A, Poulsen P, Hansen L, Rosinger S, Boehm BO, Ram R, Nguyen Q, Mehta M, Morahan G, Concannon P, Bergholdt R, Nielsen JH, Reinheckel T, von Herrath M, Vaag A, Eizirik DL, Mortensen HB, Størling J, Pociot F.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10305-10. doi: 10.1073/pnas.1402571111. Epub 2014 Jun 30.


Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes.

Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, von Herrath MG.

Diabetes. 2014 Nov;63(11):3880-90. doi: 10.2337/db14-0549. Epub 2014 Jun 19. Erratum in: Diabetes. 2016 Jan;65(1):303.


Regulatory T cells control diabetes without compromising acute anti-viral defense.

Jones CB, Pagni PP, Fousteri G, Sachithanantham S, Dave A, Rodriguez-Calvo T, Miller J, von Herrath M.

Clin Immunol. 2014 Aug;153(2):298-307. doi: 10.1016/j.clim.2014.05.006. Epub 2014 May 22.

Supplemental Content

Loading ...
Support Center